The expertise and commitment of our R&D and management teams alongside a fruitful collaboration with independent or academic research institutes and recognized contract research organizations brought Neurim Pharmaceuticals remarkable successes in drug discovery and development. Neurim Pharmaceuticals has one product registered, Circadin® – prolonged release melatonin for insomnia.
The company’s lead drug candidate Piromelatine (Neu-P11) has completed a Phase 2 clinical trial for insomnia and enters proof of concept studies in other indications.
Two more of its compounds (for neuropathic pain and Parkinson’s disease) are expected to reach final preclinical stages in the near term. Other early-stage preclinical research involves drug candidates that target diseases such as respiratory, pain and various sleep disorders.
- Neurim Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of Piromelatine for the Treatment of Insomnia
- Neurim Pharmaceuticals reports the results of stabilometric study of Circadin® demonstrating maintenance of postural stability
- Neurim Pharmaceuticals announces positive results from phase I and Ib clinical trials with Neu-P11, a sleep maintenance drug